CHAPEL HILL, N.C.--(BUSINESS WIRE)--G-Zero Therapeutics, Inc. today announced that the company has received an Advanced Technology Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This grant awards $3M to continue studies towards “Organismal Radioprotection through Pharmacological Quiescence”. The Phase II grant follows successful completion of a $600K Phase I grant awarded in late 2009.
